Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 19;11(2):345.
doi: 10.3390/diagnostics11020345.

Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer

Ciara S McNevin  1   2 , Anne-Marie Baird  3 , Ray McDermott  4   5 , Stephen P Finn  1   6
Affiliations
Review

Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer

Ciara S McNevin et al. Diagnostics (Basel). .

Abstract

Prostate Cancer (PCa) is a leading cause of morbidity and mortality among men worldwide. For most men with PCa, their disease will follow an indolent course. However, advanced PCa is associated with poor outcomes. There has been an advent of new therapeutic options with proven efficacy for advanced PCa in the last decade which has improved survival outcomes for men with this disease. Despite this, advanced PCa continues to be associated with a high rate of death. There is a lack of strong evidence guiding the timing and sequence of these novel treatment strategies. This paper focuses on a review of the strategies for diagnostic and the current evidence available for treatment selection in advanced PCa.

Keywords: CRPC; castration-resistant prostate cancer; dynamic classification; mHSPC; metastatic hormone-sensitive prostate cancer; prostate cancer; systemic therapy; treatment strategies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Treatment Landscape for advanced PC.
See this image and copyright information in PMC

References

    1. Rawla P. Epidemiology of Prostate Cancer. World J. Oncol. 2019;10:63–89. doi: 10.14740/wjon1191. - DOI - PMC - PubMed
    1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005;55:74–108. doi: 10.3322/canjclin.55.2.74. - DOI - PubMed
    1. Ferlay J., Ervik M., Lam F. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; Lyon, France: 2018. [(accessed on 29 December 2020)]. Available online: https://gco.iarc.fr/today/homescreening.
    1. Patel A.R., Klein E.A. Risk factors for prostate cancer. Nat. Clin. Pract. Urol. 2009;6:87–95. doi: 10.1038/ncpuro1290. - DOI - PubMed
    1. EAU Guidelines. European Association of Urology; Arnhem, The Netherlands: 2020.

LinkOut - more resources